Our findings suggest that the KRAS G13 and TP53 R273 mutations are associated with poor outcome in patients with KRAS+/TP53+ mutant cancer, and antiangiogenic therapy combined with therapy targeting specific genetic aberrations may be an effective treatment strategy. Here, TP53 is linked to cancer.